MedTrace Logo

Water Exchange Versus Carbon Dioxide for Colonoscopy

NCT01633333 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 473

Last updated 2014-02-12

No results posted yet for this study

Summary

Colonoscopy is commonly used in screening for colorectal cancer. A refined technique of colonoscopy involving the use of water as the sole modality to aid colonoscope insertion, water exchange, has been described in recent research papers to decrease patient discomfort and pain, and to reduce the need for sedation during colonoscopy when compared with standard air insufflation. Carbon dioxide insufflation has been described to decrease patient discomfort after colonoscopy. No randomized trial has so far compared the use of water exchange to carbon dioxide insufflation. Our hypothesis is that water exchange inflicts less discomfort to patients undergoing colonoscopy than carbon dioxide insufflation. Patients undergoing screening colonoscopy in two centers in Norway, one center in Poland and one center in The Netherlands will be enrolled and randomized to examination of either of the two methods.

Conditions

Interventions

OTHER

Water exchange colonoscopy

Water is infused and suctioned in a systematic fashion to obtain luminal view and for cleansing of the colon to facilitate colonoscope insertion. The carbon dioxide pump is turned off, only to be turned on during withdrawal from the cecum.

OTHER

Carbon dioxide insufflation

Carbon dioxide insufflation to obtain luminal view to facilitate colonoscope insertion, considered to be standard procedure.

Sponsors & Collaborators

  • South-Eastern Norway Regional Health Authority

    collaborator OTHER

  • Maria Sklodowska-Curie National Research Institute of Oncology

    collaborator OTHER

  • Erasmus Medical Center

    collaborator OTHER

  • Sorlandet Hospital HF

    lead OTHER_GOV

Principal Investigators

  • Kjetil K Garborg, MD · Sorlandet Hospital HF Kristiansand, Norway

Study Design

Allocation
RANDOMIZED
Purpose
SCREENING
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-06-30
Primary Completion
2013-12-31
Completion
2013-12-31

Countries

  • Norway
  • Poland

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01633333 on ClinicalTrials.gov